Metabolic Syndrome in Bipolar Disorders

Grover, Sandeep; Malhotra, Nidhi; Chakrabarti, Subho; Kulhara, Parmanand

doi:10.4103/0253-7176.101767

Cited by 41 publications

(34 citation statements)

References 79 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…By introducing microorganisms into the digestive tract, it is possible to change gut microbiota and may lead to beneficial changes in the gastrointestinal environment [20]. Recent clinical research has shown that in the novel treatment of MetS, the use of probiotic foods or supplements might help patients who have MetS to alleviate the severity of symptoms and that probiotics could change both anthropometric and biochemical outcomes of the individuals [21,22]. Le Barz et al [23] suggested that probiotics could be used as a complementary treatment for individuals with metabolic-related problems.…”

Section: Introductionmentioning

confidence: 99%

Probiotic Foods and Supplements Interventions for Metabolic Syndromes: A Systematic Review and Meta-Analysis of Recent Clinical Trials

Dong

Chen

et al. 2019

Ann Nutr Metab

View full text Add to dashboard Cite

Background: Individual clinical trials suggested that when treated with probiotic foods or supplements with Lactobacillus and Bifidobacterium, specific symptoms of metabolic syndrome (MetS) could be alleviated, but the results have been inconclusive. Aims: The objective of the present meta-analysis was to use anthropometric and biochemical as indicators to evaluate the efficacy of using these probiotic foods or supplements among individuals with MetS. Methods: PubMed, Cochrane Library, and CINAHL Plus were used to collect randomized controlled trials (RCTs) studies published from January 2000 to January 2018. Studies were included if they had at least one of the following outcome measurements: body mass index (BMI), waist circumference, hip circumference, waist-to-hip ratio, body fat mass (BFM), body fat percentage (BFP), systolic blood pressure (SBP), diastolic blood pressure (DBP), fasting glucose, fasting insulin, total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), triglycerides, and/or hemoglobin A1c (HbA1c). Results: The 356 records were identified during the literature search, of which only 18 met the selection criteria. The 18 RCTs with a total of 1,544 participants were included in this analysis. This meta-analysis indicated that there were no significant differences of BMI, BFM, waist circumference, hip circumference, waist-to-hip ratio, SBP, DBP, fasting glucose, fasting insulin, TC, HDL-C, HbA1c, or triglycerides between the intervention and control groups. Significant standardized mean net differences were found in the BFP and LDL-C between the intervention and control groups. Conclusions: The results indicated that probiotic food and supplement with Lactobacillus and Bifidobacterium could be used as interventions to improve specific anthropometric and biochemical outcomes among individuals with MetS. However, probiotic treatment alone could not reduce overall health risks. In addition, there were methodological drawbacks among reviewed studies, and further research is needed.

show abstract

Section: Introductionmentioning

confidence: 99%

Probiotic Foods and Supplements Interventions for Metabolic Syndromes: A Systematic Review and Meta-Analysis of Recent Clinical Trials

Dong

Chen

et al. 2019

Ann Nutr Metab

View full text Add to dashboard Cite

show abstract

“…Esse perfil de segurança para o uso de psicoestimulantes em pacientes com TAB é muito importante, uma vez que cerca de 20% dos pacientes com TAB apresentam TDAH como comorbidade 11,26 . Existem dados bem heterogêneos quanto à prevalência de síndrome metabólica (SM) em pacientes com TAB, variando de 16,7 a 67% [27][28][29] . Podemos estratificar essa prevalência de acordo com o modelo de tratamento: 36,3% para APS + EH, 36% para APS e 10,5% para EH 30 .…”

Section: Transtorno Bipolarunclassified

Lisdexanfetamina em transtornos de humor: uma revisão sistemática

Martins-da-Silva

Mosconi

Cury

et al. 2017

Debates em Psiquiatria

View full text Add to dashboard Cite

ResumoTrata-se de uma revisão sistemática da literatura na base de dados MEDLINE para avaliar os efeitos e o perfil de segurança do uso de lisdexanfetamina (LDX) em pacientes com transtorno depressivo (TD) e transtorno afetivo bipolar (TAB), utilizando apenas medical subject headings (MeSH). Foram utilizados os seguintes termos para a busca: "depressive disorder" [MeSH] OR "bipolar disorder" [MeSH] AND "lisdexamfetamine dimesylate" [MeSH]. Somente artigos em português e inglês foram selecionados, sem limitação de período. Como critério de inclusão para o nosso estudo, utilizamos apenas artigos que observaram perfil dos efeitos do uso de LDX em pacientes que apresentavam transtornos do humor, podendo apresentar transtorno de déficit de atenção e hiperatividade comórbido ou não. Foram selecionados oito artigos, mas apenas cinco foram incluídos na síntese narrativa. Encontramos poucos dados sobre o uso de LDX em transtornos do humor, mas os resultados demonstram um uso possível para potencializar o tratamento e reduzir prejuízos cognitivos em pacientes com TD e na melhora dos parâmetros da síndrome metabólica em pacientes com TAB.Palavras-chave: Transtorno bipolar, transtorno depressivo, dimesilato de lisdexanfetamina. AbstractThe present study is a systematic review of the literature published in the MEDLINE database to evaluate the effects and safety profile of lisdexamfetamine (LDX) use in patients with depressive disorder (DD) and bipolar disorder (BD), using only medical subject headings (MeSH). The following terms were used: "depressive disorder" [MeSH] . We selected articles published in Portuguese and English only, with no publication date restrictions. As an inclusion criterion, only articles that observed the profile of effects of LDX use in patients with mood disorders, with or without comorbid attention deficit and hyperactivity disorder, were included. Eight papers were selected, but only five were included in the narrative synthesis. We found few data on the use of LDX in mood disorders, but the results demonstrate a possible use to potentiate treatment and reduce cognitive impairment in patients with DD, as well as to improve metabolic syndrome parameters in patients with BD.Keywords: Bipolar disorder, depressive disorder, lisdexamfetamine dimesylate. IntroduçãoO transtorno depressivo (TD) atinge de 10 a 15% da população ao ano 1-4 , sendo mais prevalente em mulheres, na proporção de 2:1 4 . Segundo a Organização Mundial de Saúde (OMS), a depressão é a segunda doença mais incapacitante do mundo, sendo a primeira quando consideramos o tempo vivido com a incapacitação no decorrer da vida 5 . Existe uma grande dificuldade na remissão completa dos seus sintomas, sendo o prejuízo cognitivo um dos principais sintomas residuais 6 . Atualmente, estima-se que 30 a 50% dos pacientes não se recuperam totalmente, existindo um consenso de que alguns déficits cognitivos persistiriam após a remissão dos outros sintomas 7 . Além disso, algumas medicações utilizadas para o tratamento do TD podem ter um impacto ne...

show abstract

“…Individuals with serious mental illness are at a higher and significant risk of physical health problems (Grover et al . , ; Hert et al . , National Mental Health Commission ; Robson & Gray ).…”

Section: Introductionmentioning

confidence: 99%

Evaluation of a general practitioner‐led cardiometabolic clinic: Physical health profile and treatment outcomes for clients on clozapine

Coates

Woodford

Higgins

et al. 2017

Int J Mental Health Nurs

View full text Add to dashboard Cite

The present study is a review of a cardiometabolic clinic for consumers taking clozapine. This clinic was recently established and co-located with the clozapine clinic at a regional hospital in New South Wales, Australia, to enhance engagement and improve the physical health outcomes of consumers taking antipsychotic medication. A descriptive analysis of clients' (n = 73) information collected during routine care for the first 6 months of the clinic's operation, from January 2016 to July 2016, was conducted. First-visit data were analysed to establish a client profile, consisting of weight, height, blood pressure, pulse, a range of blood measurements, smoking status, alcohol consumption, and eating and exercise habits. Data collected for clients who had three or more visits with the general practitioner (n = 40) were analysed separately for outcomes. Two case studies are used to depict the service received and client profile. At the first appointment, the majority of clients had metabolic syndrome that was mostly left untreated; many of these clients were commenced on metformin. The outcomes are positive, and show that the majority of clients lost weight (82.5%) and had a reduction in body mass index (84.6%); nearly half (44.4%) had a reduction in waist circumference. The majority of clients self-reported increased physical activity (72.5%, n = 29) and positive dietary changes (77.5%, n = 31) since their first appointment. The model trialled by the cardiometabolic clinic integrated a specialist mental health and primary care service, and demonstrates success in engaging clients with severe mental illness in physical health care. Co-location is conceptualized as critical for positive patient outcomes and high levels of engagement.

show abstract

Metabolic Syndrome in Bipolar Disorders

Cited by 41 publications

References 79 publications

Probiotic Foods and Supplements Interventions for Metabolic Syndromes: A Systematic Review and Meta-Analysis of Recent Clinical Trials

Probiotic Foods and Supplements Interventions for Metabolic Syndromes: A Systematic Review and Meta-Analysis of Recent Clinical Trials

Lisdexanfetamina em transtornos de humor: uma revisão sistemática

Evaluation of a general practitioner‐led cardiometabolic clinic: Physical health profile and treatment outcomes for clients on clozapine

Contact Info

Product

Resources

About